How do you decide on rate versus rhythm control?
|
|
|
- Madeline Hudson
- 9 years ago
- Views:
Transcription
1 Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist
2 Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study 2002 RACE study 2002 Catheter ablation CABANA trial Define outcome measure Symptomatic benefit Mortality or morbidity reduction
3 A COMPARISON OF RATE CONTROL AND RHYTHM CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION 14 (0.006%) of 2033 in the rhythm control group underwent catheter ablation SR conferred a 53% mortality reduction AAD conferred a 49% mortality increase The AFFIRM investigators; N Engl J Med, Vol. 347, No. 23
4 A COMPARISON OF RATE CONTROL AND RHYTHM CONTROL IN PATIENTS WITH RECURRENT PERSISTENT ATRIAL FIBRILLATION The RACE study group Van Gelder et al N Engl J Med 2002;347:
5 Maintenance of Sinus Rhythm with an ablation strategy in patients with AF is associated with a lower risk of stroke and death Hunter et Al, Heart 2011
6 Asymptomatic persistent AF and outcome: Results of the RACE study Rienstra et al, Heart Rhythm, Vol 11, June 2014
7 Nice 2014: When to offer rate or rhythm control? Offer rate control in people with AF except where: There is a reversible cause Heart failure is felt secondary to AF New onset AF Atrial flutter For whom a rhythm control strategy is deemed more suitable based upon clinical judgement
8 June 2014
9 ESC guidelines ESC Guidelines for the management of atrial fibrillation Europace (2010)
10 Long term follow up after ablation of longstanding PsAF Rostock et al, Heart Rhythm Vol 9, 2011 Tilz et al, Jacc Vol 60; 2012
11 For whom a rhythm control strategy is deemed more suitable based upon clinical judgement Who benefits most from rhythm control? Procedural risk Redo procedures When is catheter ablation most successful? PsAF Symptom benefit Reduction in co-morbidity Patient choice Who is at most risk during catheter ablation? PsAF
12 Clinical characteristics of patients with persistent atrial fibrillation successfully treated by left atrial ablation Takahashi Y et al Circ Arrhythmia Electrophysiol 2010;3:
13 Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation AF duration Male Gender Heart failure Rostock et al, Heart Rhythm Vol 9, 2011
14 Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation? a meta-analysis D Ascenzo et al; International Journal of Cardiology 167 (2013)
15 The impact of age on the efficacy and safety of catheter ablation for longstanding persistent atrial fibrillation Xiao-Dong Zhang et al; International Journal of Cardiology 168 (2013)
16 16 Obstructive Sleep Apnoea (OSA) 720 consecutive pts Treated OSA was > 4hrs CPAP AF recurrence seen in: - 51% OSA vs 30% no OSA (p<0.0001) - 68% untreated vs 35% treated (p<0.0001) Neilan G et al. Effect of Sleep Apnea and Continuous Positive Airway Pressure on Cardiac Structure and Recurrence of Atrial Fibrillation. JAHA 2013.
17 Long-term follow-up after atrial fibrillation ablation in patients with impaired left ventricular systolic function: The importance of rhythm and rate control Nedios et al Heart Rhythm 2014;11:
18 A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial) Ejection fraction NYHA class Hunter et al. Circ Arrhythm Electrophysiol. 2014;7:31-38.
19 Catheter Ablation of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Systematic Review and Meta- Analysis 1838 patients Mean EF 40% Anselmino et al; Circ Arrhythm Electrophysiol. Epub Sept 28, 2014;
20 Predictors of complications after AF Examples: ablation Female gender Increasing age HCM Institutional experience Bohnen M et al Heart Rhythm Nov;8(11): Hoyt et al Heart Rhythm Dec;8(12): Shah RU et al. J Am Coll Cardiol Jan 10;59(2) Inoue K, Heart Rhythm Aug 15
21 June 2014
22 How do you decide on rate versus rhythm control? i.e. who do you want to ablate? Highly symptomatic secondary to AF Short duration of AF Long duration of SR post DCCV Structurally normal heart Exceptions: young heart failure patients
23 Questions?
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
How should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
Management of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
Recurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
Atrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
Presenter Disclosure Information
2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.
Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy
Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.
Management of Atrial Fibrillation in Heart Failure
Disadvantages of AV Junction Ablation Persistent AFib- no AV synchrony Ongoing risk of thromboembolism Life-long dependency on pacemaker Comparison of LA Ablation vs. AVN Ablation LA Ablation AVN Ablation
COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION
COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated
Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
Managing the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
Atrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
A 35 yo female presents increasing fatigue and shortness of breath for several days. She is found to be in atrial fibrillation.
Ryan G. Aleong Cardiology Department University of Colorado A 35 yo female presents increasing fatigue and shortness of breath for several days. She is found to be in atrial fibrillation. 1. Initiation
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate
Updated Cardiac Resynchronization Therapy Guidelines
The Ohio State University Heart and Vascular Center Updated Cardiac Resynchronization Therapy Guidelines William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology
ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?
2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them? Gaetano Senatore DIVISION OF CARDIOLOGY HOSPITAL OF CIRIE
Atrial Fibrillation (AF) March, 2013
Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one
Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center
Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long
Vorhofflimmern und Schlaganfall Ablation, Antikoagulation, Vorhofohrverschluß was wann für wen? B. Keweloh Unfallkrankenhaus Berlin
Vorhofflimmern und Schlaganfall Ablation, Antikoagulation, Vorhofohrverschluß was wann für wen? B. Keweloh Unfallkrankenhaus Berlin B. Keweloh 16.11.2013 Incidence of Atrial Fibrillation, Standard population
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
DISCLOSURES. I am a consultant for Biosense Webster St Jude Medical
Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure and an Implanted ICD/CRTD (AATAC-AF in Heart Failure) ClinicalTrials.gov Identifier: NCT00729911/
Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
Raising Sleep Apnea Awareness:
Raising Sleep Apnea Awareness: Among People with Diabetes in North Carolina, 2012 People with diabetes have more sleep problems than people without diabetes in the same age, sex, and race/ethnicity group.
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
Ablation For Atrial Fibrillation. Bill Petrellis Electrophysiologist
Ablation For Atrial Fibrillation Bill Petrellis Electrophysiologist AF is the most common arrhythmia in the Western world Prevalence 1.1% in Australia conservative estimate - 240,000 June 2009 AF is an
PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia
PRACTICAL APPROACH TO SVT Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia CONDUCTION SYSTEM OF THE HEART SA node His bundle Left bundle AV node Right
The intensity and duration of monitoring should be determined by the clinical need to establish the diagnosis
Cardiology and Vascular Medicine ESC Update Programme in Cardiology Rotterdam, June 12 th, 2012 Atrial Fibrillation ESC Guidelines: Paroxysmal Atrial Fibrillation Irene Savelieva St George s University
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Mitral Regurgitation Anatomy Mechanisms of MR Presentation Evaluation Management Repair Replace Clip
Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD
Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD Background Obstructive Sleep Apnea(OSA) Obstructive sleep apnea (OSA)
New in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
Atrial Fibrillation Peter Santucci, MD Revised May, 2008
Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is
A focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
What Can I Do about Atrial Fibrillation (AF)?
Additional Device Information 9529 Reveal XT Insertable Cardiac Monitor The Reveal XT Insertable Cardiac Monitor is an implantable patientactivated and automatically activated monitoring system that records
Il loop recorder esterno. Roberto Maggi
Il loop recorder esterno Roberto Maggi ECG monitoring and syncope In-hospital monitoring Holter Monitoring Event recorder External loop recorder Remote (at home) telemetry Implantable loop recorder External
What Should be the Primary Treatment in Atrial Fibrillation: Ventricular Rate Control or Sinus Rhythm Control with Long-term Anticoagulation?
The Journal of International Medical Research 2009; 37: 464 471 What Should be the Primary Treatment in Atrial Fibrillation: Ventricular Rate Control or Sinus Rhythm Control with Long-term Anticoagulation?
Disclosures. Anesthesia and Lead Extractions. Lead Extractions: Objectives. Lead Removal Techniques. None
Anesthesia and Lead Extractions Disclosures None Bryan Ahlgren DO Assistant Professor University of Colorado Dept of Anesthesiology Objectives Define lead extraction procedures and why Anesthesiologists
Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015
Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Disclaimer I have no relationships to disclose Do we have a cure for Atrial Fibrillation? The short
Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
Surgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
How To Improve Health Care For Remote Workers
CRM Devices and Telemonitoring Where the industry stands today Annette Brüls VP CRDM Marketing CareLink Status worldwide More than 450.000000 patients in > 4000 clinics > 30 countries 9 years of experience
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
New Approaches to Anticoagulation in Atrial Fibrillation
New Approaches to Anticoagulation in Atrial Fibrillation Hugh Calkins M.D. Nicholas J. Fortuin Professor of Cardiology Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions
Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population. Carel Jan Willem Borleffs
Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population Carel Jan Willem Borleffs The studies described in this thesis were performed at the Department
Dorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
Atrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
Xarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey
Europace (215) 17, 1596 16 doi:1.19/europace/euv2 EP WIRE Current techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey Nikolaos Dagres 1 *, Maria Grazia
on behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
INHERIT. The Lancet Diabetes & Endocrinology In press
INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn
Atrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial Lucas Boersma, WimJan van Boven, Alaaddin Yilmaz, Johannes Kelder, Maurits Wijffels
The debate: Should all AF patients see an EP consultant?
The debate: Should all AF patients see an EP consultant? Pre-debate show of hands in favour of the motion The argument for the motion: Dr Nick Kelland The argument against the motion: Dr Andy McCoye Discussion
Efficacy and Safety of Pharmacological Options for Rate Control in Atrial Fibrillation
AACN Advanced Critical Care Volume 23, Number 2, pp.120 125 2012, AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Efficacy and Safety of Pharmacological Options
ACUTE ATRIAL FIBRILLATION TREATMENT IN THE SURGICAL PATIENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
Anticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing
Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing Outline The coming crush A practical approach to clinical risk assessment Classic approach to
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE The following diagnostic tests for Obstructive Sleep Apnea (OSA) should
Establishing a Remote Monitoring Program. Martha Ferrara, FNP
Establishing a Remote Monitoring Program Martha Ferrara, FNP Establishing a Remote Monitoring Program What is Remote Monitoring? Martha Ferrara, FNP, CCDS November 2012 CIED Timeline: Cardiovascular Implantable
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
Atrial fibrillation How is treatment changing? Charles Henrikson, MD Director, Electrophysiology Service 1 February 2014
Atrial fibrillation How is treatment changing? Charles Henrikson, MD Director, Electrophysiology Service 1 February 2014 Outline Introduction Natural history of afib and stroke Current risk stratification
Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery
Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology
